Showing 5691-5700 of 6035 results for "".
- Stealth BioTherapeutics Doses First Patient in Phase 2 Study of Elamipretide for the Treatment of Dry AMDhttps://modernod.com/news/stealth-biotherapeutics-announces-dosing-of-first-patient-in-phase-2-study-of-elamipretide-for-the-treatment-of-dry-amd/2476423/Stealth BioTherapeutics announced that it has dosed the first patient in ReCLAIM-2, a phase 2 study of elamipretide in patients with dry age-related macular degeneration (AMD) with geographic atrophy. “People with dry AMD can ultimately lose central vision. However, long before that
- Quantel Medical Receives FDA Approval for ABSolu Ultrasound Platformhttps://modernod.com/news/quantel-medical-receives-fda-approval-for-absolu-ultrasound-platform/2476415/Quantel Medical announced that it has received approval from the FDA for the new A/B/S ultrasound platform: ABSolu. The ABSolu includes a new 5 ring annular technology 20MHz B probe that increases the depth of
- Alkahest Presents Positive Phase 2a Study Results of AKST4290 for Treatment-Naïve Wet AMDhttps://modernod.com/news/alkahest-presents-positive-phase-2a-study-results-of-akst4290-for-treatment-naive-wet-amd/2476414/Alkahest shared results from its open label study, ALK4290-201. The data were delivered during a podium presentation as the Abstract Winner of the First-time Presentations of Clinical Trials and Late Breakers session at the 2019 Retina World Congress. The study evaluated the therapeutic effect an
- Novartis Plans for Alcon Spin-Off on April 9, 2019https://modernod.com/news/novartis-plans-for-alcon-spin-off-on-april-9-2019/2476408/Novartis confirmed that conditions needed for the 100% spin-off of the Alcon eye care business have been met, and the spinoff is expected to be completed on April 9, 2019. Each Novartis shareholder will receive 1 Alcon share for every 5 Novartis shares/American Deposit
- Topcon Unveils New Maestro Unlimited OCT System at VEE 2019https://modernod.com/news/topcon-to-present-new-solution-for-oct-and-data-management-at-vee-2019/2476407/Topcon showcased several innovative new offerings at the Vision Expo East (VEE) conference in New York City. Topcon unveiled the new Maestro Unlimited, which pairs the Maestro 3D OCT with the new Topcon Harmony, a web-based data management application that provides unlimited device connect
- Compulink Previews New User Interface for its Optometry SMART EHR at Vision Expo Easthttps://modernod.com/news/compulink-previews-new-user-interface-for-its-optometry-smart-ehr-at-vision-expo-east/2476404/Compulink Healthcare Solutions, the creator of Advantage SMART Practice, an all-in-one EHR and practice management solution powered by artificial intelligence (AI), previewed the new user interface for its Eyecare Advantage at Vision Expo this week. Designed by a team of usability experts,
- Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japanhttps://modernod.com/news/aerie-pharmaceuticals-initiates-netarsudil-ophthalmic-solution-phase-2-clinical-trial-in-japan/2476406/Aerie Pharmaceuticals announced the commencement of patient dosing in its phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support potential regulatory submission of netarsudil ophthalmic solution in Japan. Netarsu
- Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 in Patients with Macular Edema Associated with RVOhttps://modernod.com/news/aerie-pharmaceuticals-initiates-phase-2-clinical-trial-of-ar-1105-in-patients-with-macular-edema-associated-with-rvo/2476401/Aerie Pharmaceuticals announced the commencement of patient dosing in a phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion (RVO). This phase 2 study (AR1105-CS201) will be conducted at appr
- VSP Global Names Steve Baker President of VSP Ventureshttps://modernod.com/news/vsp-global-names-steve-baker-president-of-vsp-ventures/2476398/VSP Global has announced the appointment of Steve Baker, president of Eyefinity, to lead the newly-established VSP Ventures, according to a report in VisionMonday. “Steve’
- VisionCare Announces Regulatory Approval of the CentraSight Treatment Program in Australiahttps://modernod.com/news/visioncare-announces-regulatory-approval-of-the-centrasight-treatment-program-in-australia/2476395/VisionCare announced that the Australian Department of Health Therapeutic Goods Administration has issued a Therapeutic Goods Certificate to the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), approving it for the improvement of visual acuity in patients who are 55 years and older with b